文献速递糖尿病肥胖与代谢综合征

新视野:新兴抗糖尿病药物

New Horizons: Emerging Antidiabetic Medications.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本综述总结了当前用于治疗1型和2型糖尿病的主要在研药物,重点介绍了其优势和副作用。GLP-1受体激动剂及新型GLP1与抑胃肽双受体激动剂可同时改善高血糖和肥胖,效果与代谢手术相似;SGLT2抑制剂则显示可降低心血管疾病和糖尿病肾病风险并改善结局。

要点

  • GLP-1受体激动剂和GLP1/抑胃肽双受体激动剂可同时改善高血糖和肥胖,效果与代谢手术相似。
  • SGLT2抑制剂可降低心血管疾病风险并改善结局,包括冠状动脉疾病、射血分数降低或保留的心力衰竭及糖尿病肾病。
  • 本综述总结了治疗1型和2型糖尿病的主要在研药物,并强调其优势和副作用。

核心结论

  • 糖尿病在研药物因显著的降糖效果和减重作用而更具前景。
  • 理想的2型糖尿病药物应同时针对高血糖、胰岛素抵抗和肥胖。
  • GLP-1受体激动剂和GLP1/抑胃肽双受体激动剂可对抗高血糖和肥胖两种代谢缺陷,效果与代谢手术相似。
  • SGLT2抑制剂可降低心血管疾病风险并改善结局,包括冠状动脉疾病、射血分数降低或保留的心力衰竭及糖尿病肾病。

研究设计与样本

  • 本综述总结了当前用于治疗1型和2型糖尿病的主要在研药物。

主要发现

  • GLP-1受体激动剂和GLP1/抑胃肽双受体激动剂可对抗高血糖和肥胖,效果与代谢手术相似。
  • SGLT2抑制剂可降低心血管疾病风险并改善结局,包括冠状动脉疾病、射血分数降低或保留的心力衰竭及糖尿病肾病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past century, since the discovery of insulin, the therapeutic offer for diabetes has grown exponentially, in particular for type 2 diabetes (T2D). However, the drugs in the diabetes pipeline are even more promising because of their impressive antihyperglycemic effects coupled with remarkable weight loss. An ideal medication for T2D should target not only hyperglycemia but also insulin resistance and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the new class of GLP1 and gastric inhibitory polypeptide dual RAs counteract 2 of these metabolic defects of T2D, hyperglycemia and obesity, with stunning results that are similar to the effects of metabolic surgery. An important role of antidiabetic medications is to reduce the risk and improve the outcome of cardiovascular diseases, including coronary artery disease and heart failure with reduced or preserved ejection fraction, as well as diabetic nephropathy, as shown by SGLT2 inhibitors. This review summarizes the main drugs currently under development for the treatment of type 1 diabetes and T2D, highlighting their strengths and side effects.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Mingrone G, Castagneto-Gissey L, Bornstein SR, et al. New Horizons: Emerging Antidiabetic Medications. J Clin Endocrinol Metab. 2022. PMID: 36106900. doi:10.1210/clinem/dgac499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。